{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T06:24:49Z","timestamp":1778135089834,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jdiacomp.2021.107996","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T17:47:08Z","timestamp":1626889628000},"page":"107996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["A registry-based randomised trial comparing an SGLT2 inhibitor and metformin as standard treatment of early stage type 2 diabetes (SMARTEST): Rationale, design and protocol"],"prefix":"10.1016","volume":"35","author":[{"given":"Johan","family":"Sundstr\u00f6m","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Krist\u00f3fi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ollie","family":"\u00d6stlund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Bennet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Eliasson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Jansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janeth","family":"Leksell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Almby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Lundqvist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan W.","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2021.107996_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0010","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1152\/physrev.00045.2011","article-title":"Mechanisms of diabetic complications","volume":"93","author":"Forbes","year":"2013","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00125-018-4711-2","article-title":"Global trends in diabetes complications: a review of current evidence","volume":"62","author":"Harding","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0020","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2337\/dc17-1962","article-title":"Global economic burden of diabetes in adults: projections from 2015 to 2030","volume":"41","author":"Bommer","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0025","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","article-title":"Metformin: historical overview","volume":"60","author":"Bailey","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0030","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2337\/dci19-0066","article-title":"2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0035","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1007\/s00125-017-4336-x","article-title":"Metformin: clinical use in type 2 diabetes","volume":"60","author":"Sanchez-Rangel","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0040","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","author":"UKPDS Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0045","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s00125-017-4337-9","article-title":"Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes","volume":"60","author":"Griffin","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001204","article-title":"Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials","volume":"9","author":"Boussageon","year":"2012","journal-title":"PLoS Med"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0055","article-title":"Metformin monotherapy for adults with type 2 diabetes mellitus","volume":"2020","author":"Gnesin","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0060","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0065","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0070","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0075","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0080","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0085","author":"Decentralized and virtual clinical trials"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0090","unstructured":"Swedish National Diabetes Register. Nationwide results 1996-2019. Accessed: 2021-07-04. Published online 2019. https:\/\/www.ndr.nu\/pdfs\/NationWideResults_1996-2019.pdf."},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0095","unstructured":"Nationella Diabetesregistret. \u00c5rsrapport 2020. https:\/\/www.ndr.nu\/pdfs\/Arsrapport_NDR_2020.pdf Accessed: 2021-07-04. doi:10.18158\/Hy045SYu_."},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0100","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1185\/03007995.2015.1020364","article-title":"Review of patient-reported outcome instruments measuring health-related quality of life and satisfaction in patients with type 2 diabetes treated with oral therapy","volume":"31","author":"Roborel De Climens","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0105","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/j.1463-1326.2012.01595.x","article-title":"Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus","volume":"14","author":"Davies","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13098-018-0313-x","article-title":"Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study) UMIN000016304 UMIN","volume":"10","author":"Nakajima","year":"2018","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0115","doi-asserted-by":"crossref","first-page":"0","DOI":"10.1186\/s41687-018-0030-0","article-title":"The Swedish RAND-36 health survey-reliability and responsiveness assessed in patient populations using Svensson\u2019s method for paired ordinal data","volume":"2","author":"Orwelius","year":"2018","journal-title":"J Patient-Reported Outcomes"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/ijerph15050947","article-title":"Use of diabetes treatment satisfaction questionnaire in diabetes care: importance of patient-reported outcomes","volume":"15","author":"Saisho","year":"2018","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0125","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jacbts.2019.11.007","article-title":"SGLT2 inhibitor\u2013induced sympathoinhibition: a novel mechanism for cardiorenal protection","volume":"5","author":"Herat","year":"2020","journal-title":"JACC Basic to Transl Sci"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0130","doi-asserted-by":"crossref","DOI":"10.1007\/s11886-019-1165-1","article-title":"Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure","volume":"21","author":"Scheen","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0135","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2337\/diacare.26.1.76","article-title":"Incidence of retinopathy and nephropathy in youth-onset compared with adult-onset type 2 diabetes","volume":"26","author":"Krakoff","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0140","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S2213-8587(17)30258-9","article-title":"Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis","volume":"5","author":"Birkeland","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0145","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/dom.12889","article-title":"Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes","volume":"19","author":"Nystr\u00f6m","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0150","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/dom.13627","article-title":"Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: a nationwide observational study","volume":"21","author":"Norhammar","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0155","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/dom.13612","article-title":"How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study","volume":"21","author":"Birkeland","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjdrc-2018-000627","article-title":"Eligibility of patients with type 2 diabetes for sodium-glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study","volume":"7","author":"Pintat","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/2018374","article-title":"How many patients with type 2 diabetes meet the inclusion criteria of the cardiovascular outcome trials with SGLT2 inhibitors? Estimations from a population database in a Mediterranean area","volume":"2019","author":"Canivell","year":"2019","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-020-01067-8","article-title":"Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis","volume":"19","author":"Castellana","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0224549","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: a real-world Korean study","volume":"14","author":"Chung","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0180","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/dom.13232","article-title":"Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: a network meta-analysis","volume":"20","author":"Tang","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0234065","article-title":"Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: a systematic review and meta-analysis","volume":"15","author":"Heyward","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0190","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/03009734.2018.1550453","article-title":"Swedish guidelines for registry-based randomized clinical trials","volume":"124","author":"Nyberg","year":"2019","journal-title":"Ups J Med Sci"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0195","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1056\/NEJMoa1308789","article-title":"Thrombus aspiration during ST-segment elevation myocardial infarction","volume":"369","author":"Fr\u00f6bert","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0200","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1056\/NEJMoa1706222","article-title":"Oxygen therapy in suspected acute myocardial infarction","volume":"377","author":"Hofmann","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.107996_bb0205","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa1706443","article-title":"Bivalirudin versus heparin monotherapy in myocardial infarction","volume":"377","author":"Erlinge","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872721001963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872721001963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:13:18Z","timestamp":1761005598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872721001963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1056872721001963"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2021.107996","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A registry-based randomised trial comparing an SGLT2 inhibitor and metformin as standard treatment of early stage type 2 diabetes (SMARTEST): Rationale, design and protocol","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2021.107996","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"107996"}}